Here, we characterized the pre-clinical anti-tumor activity of CC-96191 using a variety of shorter-term in vitro assays to define the principles underlying the drug’s cytolytic effects, and contrasted the results to those obtained with a potent CD33/CD3 BsAb. The gene discussed is CD33; the disease is neoplasm.